Bacteria-Based Vaccines for HIV and Other Infections
This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface.
Original patent title: “Compositions and methods for preventing and treating virus infection”
This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface. Granted in 2026.
Coverage
What does this patent actually cover?
This patent describes a method for creating vaccine candidates using bacteria. Specifically, it focuses on HIV, where bacteria are engineered to express (display) parts of the HIV virus, called MPER-derived antigens, on their outer surfaces. This display uses a natural bacterial mechanism called Gram autotransporters. When these engineered bacteria are used to immunize mice, the mice produce antibodies in their blood and vaginal washes that can bind to the bacteria. Crucially, at least one of these bacterial candidates also causes the production of antibodies that can neutralize (stop) HIV activity. This approach includes using both killed whole bacteria and live *Salmonella* to deliver these antigens.
The gap
What does this patent NOT cover?
- Vaccines that do not use bacteria as the primary delivery platform for antigens.
- Vaccines that rely on traditional methods like inactivated viruses, attenuated viruses, viral vectors, or mRNA technology.
- Vaccine candidates targeting parts of the HIV virus other than MPER-derived antigens.
- Vaccines that present antigens internally within a cell rather than on the bacterial surface.
- Bacterial vaccine platforms that do not utilize Gram autotransporters for surface antigen expression.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in using common bacteria, like *Salmonella*, as a living or killed 'display system' to present specific viral antigens, such as the MPER region of HIV, directly on their surface. This allows the immune system to recognize and respond to these viral parts in a way that could lead to protective immunity.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
HIV vaccine research
Oral vaccine development
Bacterial vector vaccines
Mucosal immunity studies
Why it matters
The bigger picture
This patent addresses the significant global challenge of developing an effective HIV vaccine. The proposed bacteria-based approach, particularly using *Salmonella*, offers the potential for an inexpensive and globally appropriate vaccine. Such a vaccine could be rapidly produced and deployed using existing technologies, which is critical for widespread access and impact in areas most affected by HIV.
Filed
August 27, 2019
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Many academic research institutions and biotechnology companies are actively exploring novel vaccine delivery platforms, including bacteria-based systems. While specific companies tied directly to this patent are unknown, firms like Vaxart focus on oral vaccine technologies, which often involve bacterial or viral vectors. Larger pharmaceutical companies also invest in diverse vaccine research pipelines, including those for challenging targets like HIV.
Market impact
This patent introduces a novel approach to vaccine development, particularly for challenging viruses like HIV, by leveraging bacteria as antigen delivery vehicles. If successful, this technology could significantly impact global health by enabling the production of inexpensive and rapidly deployable vaccines, potentially broadening access in resource-limited settings. It could also open new avenues for bacterial vaccine platforms against other infectious diseases.
Claim 1 — Plain English
What this patent covers
This patent describes a method for creating vaccine candidates using bacteria. Specifically, it focuses on HIV, where bacteria are engineered to express (display) parts of the HIV virus, called MPER-derived antigens, on their outer surfaces. This display uses a natural bacterial mechanism called Gram autotransporters. When these engineered bacteria are used to immunize mice, the mice produce antibodies in their blood and vaginal washes that can bind to the bacteria. Crucially, at least one of these bacterial candidates also causes the production of antibodies that can neutralize (stop) HIV activity. This approach includes using both killed whole bacteria and live *Salmonella* to deliver these antigens.
The clever bit
The novelty lies in using common bacteria, like *Salmonella*, as a living or killed 'display system' to present specific viral antigens, such as the MPER region of HIV, directly on their surface. This allows the immune system to recognize and respond to these viral parts in a way that could lead to protective immunity.
What it does not cover
- Vaccines that do not use bacteria as the primary delivery platform for antigens.
- Vaccines that rely on traditional methods like inactivated viruses, attenuated viruses, viral vectors, or mRNA technology.
- Vaccine candidates targeting parts of the HIV virus other than MPER-derived antigens.
- Vaccines that present antigens internally within a cell rather than on the bacterial surface.
- Bacterial vaccine platforms that do not utilize Gram autotransporters for surface antigen expression.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 12.9 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Bacteria-Based Vaccines for HIV and Other Infections (U.S. Patent No. 12,734,234). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12734234/compositions-and-methods-for-preventing-and-treating-virus-infection
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12734234"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 10357559 · 2019 · Emergent Product Development Gaithersburg Inc
How to Make Anthrax Vaccines That Survive Freezing
US 9492534 · 2016 · Genelux Corp
Using Genetically Modified Viruses to Target and Treat Cancer
US 4522811 · 1985 · Syntex USA LLC
Boosting Anti-Infective Activity with Muramyldipeptides and Liposomes
US 5397703 · 1995 · Cetus Oncology Corp
Using Insect Cells to Create Antibodies for Human Diseases
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Bacteria-Based Vaccines for HIV and Other Infections cover?
This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
This patent addresses the significant global challenge of developing an effective HIV vaccine. The proposed bacteria-based approach, particularly using *Salmonella*, offers the potential for an inexpensive and globally appropriate vaccine. Such a vaccine could be rapidly produced and deployed using existing technologies, which is critical for widespread access and impact in areas most affected by HIV.
What does this patent NOT cover?
Vaccines that do not use bacteria as the primary delivery platform for antigens.
Patent monitoring